Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of nex... Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others. 더 보기
CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Company’s next stage of growth. The...
CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced that Regina Graul, Ph.D., has been promoted to Chief Executive Officer...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.6998 | 24.5543859649 | 2.85 | 3.85 | 2.3 | 34468 | 2.59760485 | CS |
4 | 0.3998 | 12.6920634921 | 3.15 | 3.85 | 2.3 | 58213 | 3.0057936 | CS |
12 | 0.9898 | 38.6640625 | 2.56 | 9.4699 | 1.27 | 3572986 | 5.29080642 | CS |
26 | 0.0598 | 1.71346704871 | 3.49 | 9.4699 | 1.27 | 1566743 | 5.27967269 | CS |
52 | 0.6298 | 21.5684931507 | 2.92 | 9.4699 | 1.27 | 791655 | 5.27377817 | CS |
156 | -18.6502 | -84.0099099099 | 22.2 | 29.8 | 1.27 | 357196 | 7.23880791 | CS |
260 | -66.0502 | -94.8997126437 | 69.6 | 179.2 | 1.27 | 436513 | 41.39627432 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관